Two Cdn. seed companies join forces

Sep 23, 2020

WinField United Canada and Country Farm Seeds are entering a partnership that will benefit farmers across eastern Canada

By Jackie Clark
Staff Writer
Farms.com

WinField United Canada has formed a partnership with Country Farm Seeds, effective September 2020, which should benefit Canadian customers of both companies in time for the 2021 season.

C & L Seed Production Group is a production arm of Country Farm Seeds, and both are located in Blenheim, Ont. WinField United Canada is based in Saskatoon, and the company owns the CROPLAN seed brand, explained Kaitland Miller. She’s a market development manager for southern Ontario for WinField United Canada.

“We’re pumped about the partnership. The pairing is basically a win-win on both ends – especially for farmers,” she said. The partnership “allows both companies to play on their strengths, so C & L Seeds can focus on its strength of local seed production, storage and transportation. And then Winfield United Canada can focus on its strength of size, accessing elite genetics and primarily focusing on the sales and support aspect.”

WinField United Canada and Country Farm Seeds will pool resources to scale up local production of seed in eastern Canada.

“The resulting synergy of this business partnership will provide farmers in eastern Canada with high-performance genetics that are produced in Canada at a competitive price,” said a July 23 press release from WinField United.

Joining forces should allow for “improved efficiencies and locally grown products,” Miller added. The move is part of WinField United Canada’s commitment to growing its name and product offerings for the Canadian market.

For more information, visit winfieldunited.ca/ or countryfarmseeds.com/.

studio2013\iStock\Getty Images Plus photo

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.